News

The latest from Orpyx

Orpyx® has been announced as one of the twenty-seven companies in western Canada to receive funding under the WINN initiative.  WINN is a government program committed to creating jobs, promoting economic growth, and maintaining Canada's competitive advantage in the global marketplace.

Read more here.

Western Innovation (WINN) Initiative Helps Foster Commercialization of Western Canadian Projects

Calgary, AB July 2, 2014 - Orpyx Medical Technologies Inc. has been announced as one of the twenty-seven companies in western Canada to receive funding under the Western Innovation (WINN) Initiative. WINN is a government program committed to creating jobs, promoting economic growth, and maintaining Canada’s competitive advantage in the global marketplace.  In Alberta, WINN will be funding eleven projects totaling $6.81 million to support the advancement of a healthy economy.

This investment will help support development of Orpyx’s predictive data analytics for new markets like athletics.  “We are thrilled to receive the support from WINN.  This allows us to innovate faster toward a broader footprint of uses for our wearable technology platform,” states Lew Turnquist, President of Orpyx.

The Honourable Michelle Rempel, Minister of State for Western Economic Diversification said, “I am proud to support programs such as the WINN Initiative, which will assist small and medium-sized enterprises in Western Canada in bringing their ideas into the global marketplace.  Through WINN we are filling a funding gap identified by Canadian business and re-affirming our government’s commitment to providing opportunities for jobs and growth.”

About Western Innovation (WINN) Initiative:

Over its 5-year span WINN will provide up to $100 million in repayable assistance to western small- and medium-seized enterprises (SMEs).  Under WINN, SMEs can apply for funding for a variety of tasks that are essential in taking a product from the research and development stage to the market, such as: product testing and technology demonstrations, equipment purchases and installation, regulatory approval, marketing, and intellectual property protection.

About Orpyx Medical Technologies:

Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, lack of circulation, numbness, infection and ulcers in the feet, also known as peripheral neuropathy.  The diabetic foot ulcer is one of the most devastating side effects of diabetes, occurring in upwards of 15-25% of all diabetic patients over the course of their disease.  The inability to sense and respond to tissue damage can lead to the development of blisters and ulcers, which can lead to surgical amputation.  Orpyx was born out of a profound desire to find a preventative rather than reactionary solution to this problem.

Orpyx develops sensor-based technologies that address the growing demand for self-monitoring devices to better manage chronic medical conditions.  Our products focus on patient empowerment and prevention for better outcomes.

For more information, please contact:

Stephanie Zakala
Marketing & Inside Sales Manager, Orpyx Medical Technologies Inc.
stephanie.zakala@orpyx.com
403-460-0216

Download the PDF Press Release here.

Technology Veteran to Lead Commercial Operations

Calgary, AB March 17, 2014 - Orpyx Medical Technologies Inc. announced today that Lew Turnquist has been appointed as president, effective immediately.  Turnquist has served in an advisory capacity at Orpyx since 2012 but will now lead its operations as the company executes its growth strategy to develop a strong portfolio of wearable pressure sensor technologies for healthcare applications.

"Lew is an optimal fit for Orpyx and we are profoundly honoured to have him join the team.  He shares our values and our focus on innovation," states Orpyx co-founder and chief executive, Dr. Breanne Everett.  "Lew has shown himself to be a leader throughout his career and has a proven track record of success, especially with scaling early-stage technology companies."

Turnquist has over 25 years of operational and transactional experience in technology companies.  He was most recently the senior managing partner at Kirchner Private Capital Group, a US-based boutique merchant bank, where he led the firm's transactions (M&A) and operational advisory practices.  Prior to this role, Turnquist led the growth or turnaround of several early-stage technology companies including: VX Technologies Inc., a 3D measurement product company; J-Commerce Inc., a retail point-of-sale software company; and Cell-Loc Inc., a wireless location technology and services company.

"I am truly excited to be a part of a dynamic, young company at the convergence of wearable technology, neuroplasticity, and the growing problem of diabetes," said Turnquist.  "It's an opportunity to change many people's lives for the better."

Dr. Everett will maintain an active role with the company as chief executive officer.

About Orpyx Medical Technologies:

Orpyx's primary intention is to address the world's growing epidemic of diabetes and its associated complications, most notably, lack of circulation, numbness, infection and ulcers in the feet, also known as peripheral neuropathy.  The diabetic foot ulcer is one of the most devastating side effects of diabetes, occurring in upwards of 15-25% of all diabetic patients over the course of their disease.  The inability to sense and respond to tissue damage can lead to the development of blisters and ulcers, which can lead to surgical ampuatation.  Orpyx was born out of a profound desire to find a preventative rather than reactionary solution to this problem.

For more information, please contact:

Stephanie Zakala
Marketing & Inside Sales Manager, Orpyx Medical Technologies Inc.
stephanie.zakala@orpyx.com
403-460-0216

Download the PDF Press Release here.

Orpyx Medical Technologies Inc. announces early 2014 for EU status with its SurroSense Rx™ device.

Calgary, AB - November, 2013 - Orpyx Medical Technologies Inc. ("Orpyx") gains CE Mark approval for its flagship device, the SurroSense Rx™ System.  As the requirement for certain medical devices sold in the European Union, this CE Mark approval will enable Orpyx to advance sales into this market as well as conduct clinical trials.  The company anticipates international distribution of the device early 2014.

The SurroSense Rx™ System was developed to address a common complication of diabetes, peripheral neuropathy, which affects upwards of 65% of diabetics over the course of their disease and can result in debilitating complications including blisters, ulcers and amputation in some cases.  The SurroSense Rx™ System includes a sensor-embedded insert that collects pressure data from the foot and transmits the data to a smartwatch.  The user is notified when they have exceeded recommended plantar pressure and are provided with instructions as to how to offload pressure and avoid complications.  The system also tracks data over time through a web-based portal so the user can monitor their progress and improve metrics over time.  The SurroSense Rx™ System is intended to help empower diabetic patients to proactively manage peripheral neuropathy and prevent complications before they begin.

For more information, please contact:

Stephanie Zakala
Marketing & Communications Associate, Orpyx Medical Technologies Inc.
O (403) 460-0216
stephanie.zakala@orpyx.com

About Orpyx Medical Technologies:

Orpyx was created out of a profound desire to address the swiftly-growing global diabetes epidemic and its related complications, notably that of diabetic peripheral neuropathy – loss of feeling and sensory feedback in the feet experienced by an estimated 60-percent of the 350 million diabetics worldwide, that can lead to tissue damage, infection, ulceration and amputation.

Founded by Calgary surgical resident Dr. Breanne Everett, Orpyx is behind two highly innovative plantar sensory replacement systems, the SurroSense Rx™ and the SurroGait Rx™, that use pressure sensor-embedded shoe inserts to determine force exerted over the bottom of the feet, and wirelessly transmit collected information to a back pad or smartwatch worn by the user.  Orpyx products focus on patient empowerment and prevention for better outcomes.

The 24th annual ASTech Awards Gala was a spectacular night showcasing innovation and leading edge technologies from Alberta. The evening highlighted many aspects of Alberta's innovation potential and honoured the achievements of individuals and organizations that are advancing science and technology fields.  Orpyx received the award for Outstanding Science and Technology Start-Up sponsored by NAIT. Read more here.

Orpyx® Medical Technologies was announced the grand-prize winner at the 2013 TEC Edmonton VenturePrize Awards in the Fast Growth category.  This win marks three competition firsts in over a decade including: the first ever female-led company to win, first winner from Calgary, and the first company to win Student and Fast Growth competitions back-to-back. 

Calgary, AB - April 19, 2013 - Orpyx Medical Technologies was thrilled to have been awarded top honours at the 2013 TEC Edmonton VenturePrize Awards.  The competition, hosted by TEC Edmonton, recognizes and awards Alberta's top innovative and high-tech companies.  Orpyx was awarded with $100,000 in cash and in-kind services.  TEC VenturePrize is a program of TEC Edmonton, that provides training, professional support and financial incentives to help people build or enhance a viable high-growth business.

The win was a major feat for Calgary-based Orpyx.  The company made VenturePrize history as the first ever female-led company winner, first winner from Calgary and the first company to win the Student and Fast Growth VenturePrize competitions back-to-back.

“We are absolutely elated to have been awarded this year's TECVenture Fast Growth Grand Prize.  We could not be happier with the support we have received from the Alberta Tech community, and this is really the culmination of that backing.  This award will be completely invaluable in continuing to grow Orpyx, and ultimately, helping us to save limbs and save lives" states Dr. Breanne Everett, CEO and President of Orpyx Medical Technologies. 

Alberta fosters an amazing innovation and entrepreneurial environment, which can be seen in the group of finalists.  Orpyx was up against two formidable competitors including Surface Medical Inc. from Calgary and LoginRadius from Edmonton.  Orpyx plans on applying the VenturePrize Award towards the commercialization of their flagship product, the SurroSense Rx, which will be available later this year.

For more info, please contact:

Stephanie Zakala
Marketing & Communications Associate, Orpyx Medical Technologies Inc.
(403) 709-0129
stephanie.zakala@orpyx.com

About Orpyx Medical Technologies Inc.:

Orpyx was created out of a profound desire to address the swiftly-growing global diabetes epidemic and its related complications, notably that of diabetic peripheral neuropathy – loss of feeling and sensory feedback in the feet experienced by an estimated 50-percent of the 350 million diabetics worldwide, that can lead to tissue damage, infection, ulceration and amputation.

Founded by Calgary surgical resident Dr. Breanne Everett, Orpyx is behind two highly innovative plantar sensory replacement systems, the SurroSense Rx and the SurroGait Rx, that use pressure sensor-embedded shoe insoles to determine force exerted over the bottom of the feet, and wirelessly transmit collected information to a back pad, mobile device or wristwatch worn by the user.  Employing the phenomenon of neuroplasticity – the potential of the human brain to rewire itself, the patient is able to interpret the sensory stimulus felt on the back as that from the feet, and positively adjust their gait, balance, mobility and overall health as a result.

About TEC Edmonton:

TEC Edmonton helps transform high-tech discoveries into viable business opportunities.  Through our business services, TEC Edmonton helps navigate the commercialization process by providing assistance with technology evaluation, intellectual property protection, business plan development, marketing research, corporate management and funding preparation - as well as provides a home for startups in the TEC Centre incubation facility.  For more information, visit www.tecedmonton.com.

Orpyx® Medical Technologies was announced the grand-prize winner at the 2013 TEC Edmonton VenturePrize Awards in the Fast Growth category.  This win marks three competition firsts in over a decade including: the first ever female-led company to win, first winner from Calgary, and the first company to win Student and Fast Growth competitions back-to-back. 

Calgary, AB - April 19, 2013 - Orpyx Medical Technologies was thrilled to have been awarded top honours at the 2013 TEC Edmonton VenturePrize Awards.  The competition, hosted by TEC Edmonton, recognizes and awards Alberta's top innovative and high-tech companies.  Orpyx was awarded with $100,000 in cash and in-kind services.  TEC VenturePrize is a program of TEC Edmonton, that provides training, professional support and financial incentives to help people build or enhance a viable high-growth business.

The win was a major feat for Calgary-based Orpyx.  The company made VenturePrize history as the first ever female-led company winner, first winner from Calgary and the first company to win the Student and Fast Growth VenturePrize competitions back-to-back.

“We are absolutely elated to have been awarded this year's TECVenture Fast Growth Grand Prize.  We could not be happier with the support we have received from the Alberta Tech community, and this is really the culmination of that backing.  This award will be completely invaluable in continuing to grow Orpyx, and ultimately, helping us to save limbs and save lives" states Dr. Breanne Everett, CEO and President of Orpyx Medical Technologies. 

Alberta fosters an amazing innovation and entrepreneurial environment, which can be seen in the group of finalists.  Orpyx was up against two formidable competitors including Surface Medical Inc. from Calgary and LoginRadius from Edmonton.  Orpyx plans on applying the VenturePrize Award towards the commercialization of their flagship product, the SurroSense Rx, which will be available later this year.

For more info, please contact:

Stephanie Zakala
Marketing & Communications Associate, Orpyx Medical Technologies Inc.
(403) 709-0129
stephanie.zakala@orpyx.com

About Orpyx Medical Technologies Inc.:

Orpyx was created out of a profound desire to address the swiftly-growing global diabetes epidemic and its related complications, notably that of diabetic peripheral neuropathy – loss of feeling and sensory feedback in the feet experienced by an estimated 50-percent of the 350 million diabetics worldwide, that can lead to tissue damage, infection, ulceration and amputation.

Founded by Calgary surgical resident Dr. Breanne Everett, Orpyx is behind two highly innovative plantar sensory replacement systems, the SurroSense Rx and the SurroGait Rx, that use pressure sensor-embedded shoe insoles to determine force exerted over the bottom of the feet, and wirelessly transmit collected information to a back pad, mobile device or wristwatch worn by the user.  Employing the phenomenon of neuroplasticity – the potential of the human brain to rewire itself, the patient is able to interpret the sensory stimulus felt on the back as that from the feet, and positively adjust their gait, balance, mobility and overall health as a result.

About TEC Edmonton:

TEC Edmonton helps transform high-tech discoveries into viable business opportunities.  Through our business services, TEC Edmonton helps navigate the commercialization process by providing assistance with technology evaluation, intellectual property protection, business plan development, marketing research, corporate management and funding preparation - as well as provides a home for startups in the TEC Centre incubation facility.  For more information, visit www.tecedmonton.com.

2013 TIPS Innovation Challenge

February 14, 2013

Awards  

To foster the development of the best new technology and innovations in the field of cosmetic & reconstructive surgery the Plastic Surgery Foundation launched the inaugural TIPS Innovation Challenge.  Orpyx® was selected as one of the top two submissions with the best technological inventions.
The ASTech Awards are the premiere acknowledgement of scientific and technological achievement in Alberta and are announced at a black-tie gala banquet held annually in Calgary or Edmonton. The awards have grown to encompass more than a dozen distinct categories. Collectively, the honourees demonstrate the abundance of outstanding work occurring in Alberta’s science and technology community. Dr. Everett won in the Leaders of Tomorrow category.
Orpyx® CEO, Dr. Breanne Everett, was recognized as one of Avenue Magazine's Top 40 Under 40. When the issue was revealed at an industry gala event at Downtown Calgary's CORE on November 1, 2012, Breanne was surprised to learn that her photo made the cover! Avenue Calgary‘s Top 40 Under 40 celebrates Calgarians under the age of 40 who excel in their respective fields, give back to their community & raise the profile of the city. Read the article.